Desmoda：最新获美国FDA批准、适用于所有年龄组的口服去氨加压素溶液

文献信息

中文摘要

中枢性尿崩症（CDI）是一种不常见的疾病，其特征为血管加压素分泌不足，导致多尿、多饮，并可能出现脱水和电解质紊乱。去氨加压素是血管加压素的合成形式，仍是治疗的基石。Desmoda是一种获美国食品药品监督管理局批准的去氨加压素口服液体制剂，提供了一种新颖的即用型选择，适用于所有年龄人群，尤其是婴儿和吞咽困难者。它便于按体重进行精确给药，无需处理片剂或冷藏。Desmoda标志着CDI治疗的重要进展；然而，需警惕低钠血症及其在肾功能损害患者中的使用。

英文摘要

Central diabetes insipidus (CDI) is an uncommon condition characterized by deficient vasopressin secretion, resulting in polyuria, polydipsia, and the potential for dehydration and electrolyte disturbances. Desmopressin, a synthetic form of vasopressin, remains the cornerstone of treatment. Desmoda, an oral liquid formulation of desmopressin approved by the United States Food and Drug Administration, provides a novel, ready-to-use option appropriate for all age demographics, especially infants and individuals with dysphagia. It facilitates accurate, weight-based dosing without requiring tablet handling or refrigeration. Desmoda signifies significant progress in CDI care; however, caution is warranted regarding hyponatremia and its use in patients with renal impairment.